Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Wendy B London, Ph.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Shimano KA, Grace RF, Despotovic JM, Neufeld EJ, Klaassen RJ, Bennett CM, Ma C, London WB, Neunert C. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 Aug 27; 11(8):e044885. PMID: 34452956.
    Citations:    Fields:    
  2. Meany HJ, Widemann BC, Hinds PS, Bagatell R, Shusterman S, Stern E, Jayaprakash N, Peer CJ, Figg WD, Hall OM, Sissung TM, Kim A, Fox E, London WB, Rodriguez-Galindo C, Minturn JE, Dome JS. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 Aug 12; e29282. PMID: 34383370.
    Citations:    Fields:    
  3. Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 Aug 01; 45(8):1075-1081. PMID: 33739795.
    Citations:    Fields:    
  4. Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 Jul 28; JCO2100278. PMID: 34319759.
    Citations:    Fields:    
  5. Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 Jul 01; 4(7):e2116248. PMID: 34236408.
    Citations:    Fields:    
  6. Chonat S, Eber SW, Holzhauer S, Kollmar N, Morton DH, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M, Ravindranath Y, Wang H, Breakey VR, Sheth S, Bradeen HA, Al-Sayegh H, London WB, Grace RF. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 Sep; 68(9):e29148. PMID: 34125488.
    Citations:    Fields:    
  7. Gamble LD, Purgato S, Henderson MJ, Di Giacomo S, Russell AJ, Pigini P, Murray J, Valli E, Milazzo G, Giorgi FM, Cowley M, Ashton LJ, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings RL, Tonini GP, Fong K, Vaksman Z, Diskin SJ, Maris JM, London WB, Marshall GM, Ziegler DS, Hogarty MD, Perini G, Norris MD, Haber M. A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers (Basel). 2021 Apr 09; 13(8). PMID: 33918978.
    Citations:    
  8. Granger MM, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 06; 27(6):490.e1-490.e8. PMID: 33823167.
    Citations:    Translation:Humans
  9. Ma C, Sridharan M, Al-Sayegh H, Li A, Guo D, Auclair M, Kuragayala V, Bandaru C, Milne D, Cruse H, Beaudoin R, Orechia J, Bickel J, London WB. Building a Harmonized Datamart by Integrating Cross-Institutional Systems of Clinical, Outcome, and Genomic Data: The Pediatric Patient Informatics Platform (PPIP). JCO Clin Cancer Inform. 2021 02; 5:202-215. PMID: 33591797.
    Citations:    Fields:    Translation:Humans
  10. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15; 27(8):2179-2189. PMID: 33504555.
    Citations: 8     Fields:    
  11. Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D, Boardman K, Khelladi R, Shaw K, Negre H, Negre O, Nikiforow S, Ritz J, Pai SY, London WB, Dansereau C, Heeney MM, Armant M, Manis JP, Williams DA. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215. PMID: 33283990.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  12. Moreno L, Guo D, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, Ladenstein R, Valteau-Couanet D, Cohn SL, Pearson ADJ, London WB. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794. PMID: 33205902.
    Citations:    Fields:    Translation:Humans
  13. Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787. PMID: 33140540.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  14. Tao T, Shi H, Wang M, Perez-Atayde AR, London WB, Gutierrez A, Lemos B, Durbin AD, Look AT. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. J Exp Med. 2020 10 05; 217(10). PMID: 32728700.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  15. Liang WH, Federico SM, London WB, Naranjo A, Irwin MS, Volchenboum SL, Cohn SL. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905. PMID: 33058692.
    Citations: 2     Fields:    Translation:Humans
  16. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721. PMID: 32931402.
    Citations:    Fields:    Translation:Humans
  17. Bitterman DS, Bona K, Laurie F, Kao PC, Terezakis SA, London WB, Haas-Kogan DA. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 09 01; 6(9):1465-1468. PMID: 32910158.
    Citations: 2     Fields:    Translation:Humans
  18. Bitterman DS, Bona K, Laurie F, Kao PC, Terezakis SA, London WB, Haas-Kogan DA. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 Aug 06. PMID: 32761120.
    Citations:    Fields:    
  19. Zhong CS, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Kao PC, London WB, Marghoob AA, Phung TL, Pope E, Eichenfield LF, Huang JT. Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. J Am Acad Dermatol. 2021 May; 84(5):1472-1476. PMID: 32687967.
    Citations:    Fields:    Translation:Humans
  20. Al-Samkari H, van Beers EJ, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N, Despotovic JM, Pospíšilová D, Knoll CM, Kwiatkowski JL, Pastore YD, Thompson AA, Wlodarski MW, Ravindranath Y, Rothman JA, Wang H, Holzhauer S, Breakey VR, Verhovsek MM, Kunz J, Sheth S, Sharma M, Rose MJ, Bradeen HA, McNaull MN, Addonizio K, Al-Sayegh H, London WB, Grace RF. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Jul 03. PMID: 32619047.
    Citations:    Fields:    
  21. Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob AA. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol. 2020 Nov; 83(5):1274-1281. PMID: 32622142.
    Citations:    Fields:    Translation:Humans
  22. Liu KX, Naranjo A, Zhang FF, DuBois SG, Braunstein SE, Voss SD, Khanna G, London WB, Doski JJ, Geiger JD, Kreissman SG, Grupp SA, Diller LR, Park JR, Haas-Kogan DA. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. PMID: 32530765.
    Citations: 5     Fields:    Translation:Humans
  23. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020 08; 67(8):e28359. PMID: 32472746.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  24. Al-Samkari H, Addonizio K, Glader B, Morton DH, Chonat S, Thompson AA, Kuo KHM, Ravindranath Y, Wang H, Rothman JA, Kwiatkowski JL, Kung C, Kosinski PA, Al-Sayegh H, London WB, Grace RF. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. Br J Haematol. 2021 03; 192(6):1092-1096. PMID: 32463523.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  25. Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol. 2020 07 01; 38(19):2160-2169. PMID: 32343642.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  26. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918. PMID: 32315273.
    Citations: 4     Fields:    Translation:Humans
  27. Bianchi P, Fermo E, Lezon-Geyda K, van Beers EJ, Morton HD, Barcellini W, Glader B, Chonat S, Ravindranath Y, Newburger PE, Kollmar N, Despotovic JM, Verhovsek M, Sharma M, Kwiatkowski JL, Kuo KHM, Wlodarski MW, Yaish HM, Holzhauer S, Wang H, Kunz J, Addonizio K, Al-Sayegh H, London WB, Andres O, van Wijk R, Gallagher PG, Grace RFF. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol. 2020 05; 95(5):472-482. PMID: 32043619.
    Citations: 10     Fields:    Translation:Humans
  28. Hofmann I, Avagyan S, Stetson A, Guo D, Al-Sayegh H, London WB, Lehmann L. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. Biol Blood Marrow Transplant. 2020 06; 26(6):1124-1130. PMID: 32088370.
    Citations: 5     Fields:    Translation:HumansCells
  29. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. PMID: 31454045.
    Citations: 33     Fields:    Translation:Humans
  30. Li EB, Song JS, Huang JT, Hawryluk EB, London WB, Guo D, Sridharan M, Fisher DE, Rea CJ, Lehmann LE, Duncan CN. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Nov; 36(6):882-886. PMID: 31410910.
    Citations:    Fields:    Translation:Humans
  31. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. PMID: 31386611.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  32. Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 10 15; 25(20):6044-6051. PMID: 31358541.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  33. Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 08; 66(8):e27819. PMID: 31115156.
    Citations: 5     Fields:    Translation:Humans
  34. Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A, Phung TL, Pope E, Gerami P, Schmidt B, Robinson S, Bartenstein D, Bahrani E, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Tran G, Travis K, Wolner Z, Eichenfield LF. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr. 2019 08; 211:152-158. PMID: 31103258.
    Citations: 3     Fields:    Translation:Humans
  35. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. PMID: 30968542.
    Citations: 1     Fields:    Translation:Humans
  36. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. PMID: 30880335.
    Citations:    Fields:    
  37. Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 05; 112:66-79. PMID: 30947024.
    Citations: 7     Fields:    Translation:Humans
  38. Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, London WB, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Sci Transl Med. 2019 01 30; 11(477). PMID: 30700572.
    Citations: 22     Fields:    Translation:AnimalsCells
  39. Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 12; 2:1-15. PMID: 30652588.
    Citations: 6     Fields:    Translation:Humans
  40. Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 04; 66(4):e27556. PMID: 30479064.
    Citations: 13     Fields:    Translation:Humans
  41. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124. PMID: 30444686.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  42. Esrick EB, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney MM, London WB, Biasco L, Asmal M, Williams DA, Biffi A. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Adv. 2018 10 09; 2(19):2505-2512. PMID: 30282642.
    Citations: 13     Fields:    Translation:HumansCells
  43. Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst. 2018 10 01; 110(10):1084-1093. PMID: 29514301.
    Citations: 18     Fields:    Translation:HumansCells
  44. van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA, Sharma M, Neufeld EJ, Sheth S, Despotovic JM, Kollmar N, Pospíšilová D, Knoll CM, Kuo K, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Verhovsek M, Kunz J, McNaull MA, Rose MJ, Bradeen HA, Addonizio K, Li A, Al-Sayegh H, London WB, Grace RF. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 02; 104(2):e51-e53. PMID: 30213831.
    Citations: 9     Fields:    Translation:Humans
  45. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. PMID: 30131550.
    Citations: 16     Fields:    Translation:Humans
  46. Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1641. PMID: 30046297.
    Citations: 3     Fields:    
  47. Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1355. PMID: 29967609.
    Citations: 20     Fields:    
  48. Heeney MM, Guo D, De Falco L, Campagna DR, Olbina G, Kao PP, Schmitz-Abe K, Rahimov F, Gutschow P, Westerman K, Ostland V, Jackson T, Klaassen RJ, Markianos K, Finberg KE, Iolascon A, Westerman M, London WB, Fleming MD. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood. 2018 07 26; 132(4):448-452. PMID: 29895660.
    Citations: 5     Fields:    Translation:Humans
  49. Northman L, Morris M, Loucas C, Ross S, Muriel AC, Guo D, London WB, Manley P, Ullrich NJ. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):276-286. PMID: 29600747.
    Citations:    Fields:    Translation:Humans
  50. Huang JT, Song JS, Hawryluk EB, London WB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018 Aug; 79(2):230-237. PMID: 29588248.
    Citations: 1     Fields:    Translation:Humans
  51. Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D, Al-Sayegh H, London WB, Gallagher PG, Zanella A, Barcellini W. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018 05 17; 131(20):2183-2192. PMID: 29549173.
    Citations: 20     Fields:    Translation:HumansCells
  52. Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, Ecklund K, Janeway KA. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018 04; 65(4). PMID: 29251406.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  53. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2018 Jan 19; 9(5):6416-6432. PMID: 29464082.
    Citations: 9     Fields:    
  54. Ananth P, Ma C, Al-Sayegh H, Kroon L, Klein V, Wharton C, Hallez E, Braun I, Michelson K, Rosenberg AR, London W, Wolfe J. Provider Perspectives on Use of Medical Marijuana in Children With Cancer. Pediatrics. 2018 01; 141(1). PMID: 29233937.
    Citations: 7     Fields:    Translation:Humans
  55. de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34. PMID: 29376112.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  56. O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). PMID: 29077256.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  57. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196. PMID: 28972044.
    Citations: 19     Fields:    Translation:HumansCells
  58. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017 Dec 15; 123(24):4914-4923. PMID: 28885700.
    Citations: 27     Fields:    Translation:Humans
  59. Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. PMID: 28733870.
    Citations: 23     Fields:    Translation:Humans
  60. Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Nov 01; 123(21):4224-4235. PMID: 28696504.
    Citations: 34     Fields:    Translation:Humans
  61. Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017; 8:675. PMID: 28659916.
    Citations: 8     Fields:    
  62. Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 07; 18(7):946-957. PMID: 28549783.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  63. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. PMID: 28471719.
    Citations: 46     Fields:    Translation:Humans
  64. La Quaglia MP, Haas-Kogan D, Park J, Kreissman SG, von Allmen D, Davidoff A, London WB, Khanna G. Reply to J. Stenman et al. J Clin Oncol. 2017 06 10; 35(17):1966-1967. PMID: 28422554.
    Citations:    Fields:    Translation:Humans
  65. Song JS, London WB, Hawryluk EB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN, Huang JT. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997. PMID: 28368380.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  66. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185. PMID: 28033528.
    Citations: 18     Fields:    Translation:HumansCells
  67. Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2017 02 15; 77(4):971-981. PMID: 27923830.
    Citations: 26     Fields:    Translation:HumansCells
  68. von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP. Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 10; 35(2):208-216. PMID: 27870572.
    Citations: 14     Fields:    Translation:Humans
  69. Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. PMID: 28068235.
    Citations: 6     Fields:    Translation:Humans
  70. Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget. 2016 Aug 23; 7(34):54937-54951. PMID: 27448979.
    Citations: 8     Fields:    Translation:HumansCells
  71. Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS One. 2016; 11(8):e0161039. PMID: 27513929.
    Citations: 4     Fields:    Translation:Humans
  72. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10. PMID: 27434878.
    Citations: 15     Fields:    Translation:Humans
  73. Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016 07; 22(7):1275-1283. PMID: 27090959.
    Citations: 2     Fields:    Translation:Humans
  74. Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CWM, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. PMID: 26822149.
    Citations: 61     Fields:    
  75. O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. Cancer Res. 2016 06 15; 76(12):3604-17. PMID: 27197171.
    Citations: 9     Fields:    Translation:HumansCells
  76. Treister NS, London WB, Guo D, Malsch M, Verrill K, Brewer J, Margossian S, Duncan C. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. Photomed Laser Surg. 2016 Apr; 34(4):178-84. PMID: 26982624.
    Citations: 9     Fields:    Translation:Humans
  77. Ullrich CK, Lehmann L, London WB, Guo D, Sridharan M, Koch R, Wolfe J. End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016 06; 22(6):1049-1055. PMID: 26903381.
    Citations: 20     Fields:    Translation:Humans
  78. Tubman VN, Marshall R, Jallah W, Guo D, Ma C, Ohene-Frempong K, London WB, Heeney MM. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatr Blood Cancer. 2016 Apr; 63(4):671-6. PMID: 26739520.
    Citations: 18     Fields:    Translation:HumansPHPublic Health
  79. Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15; 122(6):935-45. PMID: 26709890.
    Citations: 19     Fields:    Translation:Humans
  80. Poorvu PD, Barton SE, Duncan CN, London WB, Laufer MR, Lehmann LE, Marcus KJ. Use and Effectiveness of Gonadotropin-Releasing Hormone Agonists for Prophylactic Menstrual Suppression in Postmenarchal Women Who Undergo Hematopoietic Cell Transplantation. J Pediatr Adolesc Gynecol. 2016 Jun; 29(3):265-8. PMID: 26506031.
    Citations: 3     Fields:    Translation:Humans
  81. Bona K, London WB, Guo D, Frank DA, Wolfe J. Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort Study. Pediatr Blood Cancer. 2016 Jan; 63(1):105-11. PMID: 26398865.
    Citations: 19     Fields:    Translation:Humans
  82. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17. PMID: 26304901.
    Citations: 198     Fields:    Translation:Humans
  83. Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 2015 Jul 30; 6(21):18558-76. PMID: 26053094.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  84. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63. PMID: 26035700.
    Citations: 45     Fields:    Translation:Humans
  85. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015 Aug; 62(8):1305-16. PMID: 25810263.
    Citations: 11     Fields:    Translation:Humans
  86. Forester CM, Sartain SE, Guo D, Harris MH, Weinberg OK, Fleming MD, London WB, Williams DA, Hofmann I. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol. 2015 Apr; 90(4):320-6. PMID: 25580823.
    Citations: 5     Fields:    Translation:Humans
  87. Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):913-9. PMID: 25667988.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  88. Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015 Feb; 72(2):314-20. PMID: 25481710.
    Citations: 4     Fields:    Translation:Humans
  89. Matthay KK, London WB, Maris J, Adamson PC, Park JR. Reply to N.-K.V. Cheung et al. J Clin Oncol. 2014 Dec 20; 32(36):4174-5. PMID: 25403223.
    Citations: 1     Fields:    Translation:Humans
  90. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94. PMID: 25517749.
    Citations: 121     Fields:    Translation:HumansCells
  91. Bona K, London WB, Guo D, Abel G, Lehmann L, Wolfe J. Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families. Biol Blood Marrow Transplant. 2015 Feb; 21(2):312-8. PMID: 25445021.
    Citations: 8     Fields:    Translation:Humans
  92. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer. 2015 Jan; 62(1):60-4. PMID: 25308760.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  93. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D, Harris CE, Hopkins G, Lehmann LE, Lim A, London WB, van der Loo JC, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, Thrasher AJ. A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 09; 371(15):1407-17. PMID: 25295500.
    Citations: 116     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  94. Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9. PMID: 25207821.
    Citations: 11     Fields:    Translation:Humans
  95. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. PMID: 25154816.
    Citations: 38     Fields:    Translation:Humans
  96. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9. PMID: 25044743.
    Citations: 12     Fields:    Translation:Humans
  97. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014 Jun 30; 5(12):4257-68. PMID: 24952595.
    Citations: 10     Fields:    Translation:HumansCells
  98. Kesselheim JC, Sun P, Woolf AD, London WB, Boyer D. Balancing education and service in graduate medical education: data from pediatric trainees and program directors. Acad Med. 2014 Apr; 89(4):652-7. PMID: 24556769.
    Citations: 3     Fields:    Translation:Humans
  99. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35. PMID: 24663047.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  100. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52. PMID: 24549002.
    Citations: 5     Fields:    Translation:HumansCells
  101. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78. PMID: 24560446.
    Citations: 17     Fields:    Translation:Humans
  102. Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. PMID: 24482038.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  103. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20; 32(6):527-34. PMID: 24419114.
    Citations: 23     Fields:    Translation:Humans
  104. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. PMID: 24347462.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  105. Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35. PMID: 24038992.
    Citations: 26     Fields:    Translation:HumansCells
  106. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26. PMID: 23901000.
    Citations: 30     Fields:    Translation:HumansCells
  107. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. PMID: 23890779.
    Citations: 93     Fields:    Translation:HumansCTClinical Trials
  108. Robison NJ, Prabhu SP, Sun P, Chi SN, Kieran MW, Manley PE, Cohen LE, Goumnerova L, Smith ER, Scott RM, London WB, Ullrich NJ. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. PMID: 23670879.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  109. Kirby C, Ambros PF, Billiter D, London WB, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. AMIA Jt Summits Transl Sci Proc. 2013; 2013:103. PMID: 24303312.
    Citations:    
  110. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. PMID: 23440556.
    Citations: 48     Fields:    Translation:Humans
  111. Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. PMID: 23334272.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  112. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84. PMID: 23334666.
    Citations: 404     Fields:    Translation:HumansCells
  113. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Mattay KM, Hogarty M. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013 Jun; 60(6):985-93. PMID: 23255319.
    Citations: 118     Fields:    Translation:Humans
  114. Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9. PMID: 23243203.
    Citations: 15     Fields:    Translation:Humans
  115. Myers LC, Sun P, Brennan LL, London WB, Guinan EC. Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol. 2013 Mar; 30(2):116-30. PMID: 23189973.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  116. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. PMID: 22964741.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  117. Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834. PMID: 23050139.
    Citations: 20     
  118. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22. PMID: 22976801.
    Citations: 49     Fields: